References
- Aft R, Zhang F, Gius D (2002). Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. British J Cancer, 87, 805-12. https://doi.org/10.1038/sj.bjc.6600547
- Aghaee F, Pirayesh Islamian J, Baradaran B (2012). Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy. J Breast Cancer, 15, 141-7. https://doi.org/10.4048/jbc.2012.15.2.141
- Ahmad I, Mustafa E, Mustafa N, et al (2010). 2DG enhances the susceptibility of breast cancer cells to doxorubicin. Open Life Sci, 5, 739-48.
- Basler M, Lauer C, Beck U, et al (2009). The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol, 183, 6145-50. https://doi.org/10.4049/jimmunol.0901596
- Ben Sahra I, Laurent K, Giuliano S, et al (2010). Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res, 70, 2465-75. https://doi.org/10.1158/0008-5472.CAN-09-2782
- DiPaola RS, Dvorzhinski D, Thalasila A, et al (2008). Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate, 68, 1743-52. https://doi.org/10.1002/pros.20837
-
Duan S, Skaar JR, Kuchay S, et al (2011). mTOR generates an auto-amplification loop by triggering the
${\beta}$ TrCP-and CK1${\alpha}$ -dependent degradation of DEPTOR. Molecular cell, 44, 317-24. https://doi.org/10.1016/j.molcel.2011.09.005 - Dwarakanath BS (2009). Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro. J Cancer Res Ther, 5, 27-31. https://doi.org/10.4103/0973-1482.55137
- Edelmann MJ, Nicholson B, Kessler BM (2011). Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med, 13, 35. https://doi.org/10.1017/S1462399411002031
- Emanuele MJ, Elia AE, Xu Q, et al (2011). Global identification of modular cullin-RING ligase substrates. Cell, 147, 459-74. https://doi.org/10.1016/j.cell.2011.09.019
- Heminger K, Jain V, Kadakia M, et al (2006). Altered gene expression induced by ionizing radiation and glycolytic inhibitor 2-deoxy-glucose in a human glioma cell line: implications for radio sensitization. Cancer Biol Ther, 5, 815-23. https://doi.org/10.4161/cbt.5.7.2812
- Jia L, Li H, Sun Y (2011). Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia (New York, NY), 13, 561. https://doi.org/10.1593/neo.11420
- Kern KA, Norton JA (1987). Inhibition of established rat fibrosarcoma growth by the glucose antagonist 2-deoxy-Dglucose. Surgery, 102, 380-5.
- Lee YJ, Galoforo SS, Berns CM, et al (1997). Glucose deprivation-induced cytotoxicity in drug resistant human breast carcinoma MCF-7/ADR cells: role of c-myc and bcl-2 in apoptotic cell death. J Cell Sci, 110, 681-6.
- Liao H, Liu XJ, Blank JL, et al (2011). Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics, 10, 111.
- Lin H-K, Chen Z, Wang G, et al (2010a). Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature, 464, 374-9. https://doi.org/10.1038/nature08815
- Lin JJ, Milhollen MA, Smith PG, et al (2010b). NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res, 70, 10310-20. https://doi.org/10.1158/0008-5472.CAN-10-2062
- Lin X, Zhang F, Bradbury CM, et al (2003). 2-Deoxy-D-glucoseinduced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res, 63, 3413-7.
-
Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the
$2^{-{\Delta}{\Delta}CT}$ method. Methods, 25, 402-8. https://doi.org/10.1006/meth.2001.1262 - Luo Z, Pan Y, Jeong LS, et al (2012a). Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells. Autophagy, 8, 1677-9. https://doi.org/10.4161/auto.21484
- Luo Z, Yu G, Lee HW, et al (2012b). The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res, 72, 3360-71. https://doi.org/10.1158/0008-5472.CAN-12-0388
- Mackintosh C, Garcia-Dominguez DJ, Ordonez JL, et al (2013). WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene, 32, 1441-51. https://doi.org/10.1038/onc.2012.153
- Milhollen MA, Narayanan U, Soucy TA, et al (2011). Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res, 71, 3042-51. https://doi.org/10.1158/0008-5472.CAN-10-2122
- Milhollen MA, Traore T, Adams-Duffy J, et al (2010). MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood, 116, 1515-23. https://doi.org/10.1182/blood-2010-03-272567
- Nawrocki ST, Griffin P, Kelly KR, et al (2012). MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert opinion investigational drugs, 21, 1563-73. https://doi.org/10.1517/13543784.2012.707192
- Simons AL, Mattson DM, Dornfeld K, et al (2009). Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J Cancer Res Ther, 5, 2. https://doi.org/10.4103/0973-1482.55133
- Soucy TA, Smith PG, Milhollen MA, et al (2009). An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature, 458, 732-6. https://doi.org/10.1038/nature07884
- Subarnas A, Diantini A, Abdulah R, et al (2012). Antiproliferative activity of primates-consumed plants against MCF-7 human breast cancer cell lines. E3 J Med Res, 1, 38-43.
- Sun Y, Li H (2013). Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein cell, 4, 103-16. https://doi.org/10.1007/s13238-012-2105-7
- Swords RT, Kelly KR, Smith PG, et al (2010). Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood, 115, 3796-800. https://doi.org/10.1182/blood-2009-11-254862
- Tan M, Li Y, Yang R, et al (2011). Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid. PLoS One, 6, 27726. https://doi.org/10.1371/journal.pone.0027726
- Wei D, Li H, Yu J, et al (2012). Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res, 72, 282-93. https://doi.org/10.1158/0008-5472.CAN-11-2866
- Yang D, Tan M, Wang G, et al (2012a). The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS One, 7, 34079. https://doi.org/10.1371/journal.pone.0034079
- Yang D, Zhao Y, Liu J, et al (2012b). Protective autophagy induced by RBX1/ROC1 knockdown or CRL inactivation via modulating the DEPTOR-MTOR axis. Autophagy, 8, 1856-8. https://doi.org/10.4161/auto.22024
- Yao W, Wu J, Yu G, et al (2014). Suppression of tumor angiogenesis by targeting the protein neddylation pathway. Cell Death Disease, 5, 1059. https://doi.org/10.1038/cddis.2014.21
- Zhang F, Aft RL (2009). Chemosensitizing and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells. J Cancer Res Ther, 5, 41-3.
- Zhao Y, Xiong X, Jia L, et al (2012). Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Disease, 3, 386. https://doi.org/10.1038/cddis.2012.125
Cited by
- Golgi apparatus dis- and reorganizations studied with the aid of 2-deoxy-d-glucose and visualized by 3D-electron tomography vol.147, pp.4, 2017, https://doi.org/10.1007/s00418-016-1515-7
- Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML vol.131, pp.13, 2018, https://doi.org/10.1182/blood-2017-09-805895
- Moving Breast Cancer Therapy up a Notch vol.8, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2018.00518